A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal

Undefined
10
Average: 10 (1 vote)

A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.

 

 

Sub-category:

Other: developmental therapeutics: immunotherapy

 

Category:

Developmental Therapeutics: Immunotherapy

 

Meeting:

2009 ASCO Annual Meeting

 

Session Type and Session Title:

General Poster Session, Developmental Therapeutics: Immunotherapy

 

Abstract No:

3050

 

Citation:

J Clin Oncol 27:15s, 2009 (suppl; abstr 3050)

 

Author(s):

A. Chatterjee, S. Bhattacharya, A. K. Chatterjee, J. Biswas, B. Mukhopadhyay; Critical Cancer Management Research Centre, Kolkata, India; Chittaranjan National Cancer Institute, Kolkata, India; National Institute of Technology, Durgapur, India

Abstract:

Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers. The primary outcome measures of the study were (1) to assess the radiological tumor response; (2) to assess how many participants survived at least 1 year, 2 years, 3 years, 4 years, and finally, 5 years after the beginning of the study. The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any. Methods: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.

Results: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study. According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV. According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. 126 (79.75%) of them survived at least 1 year, 99 (62.66%) of them survived at least 2 years, 87 (55.06%) of them survived at least 3 years, 76 (48.10%) of them survived at least 4 years, and 62 (39.24%) of them survived at least 5 years. These participants did not receive any other conventional or investigational cancer treatments. The participants report no side effects from the drug psorinum.

Conclusions: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers. Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.